ClinicalTrials.gg
Not yet recruitingNCT04630847Updated Sep 18, 2026

Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders

A Phase 1 interventional study of Fecal Microbiota Transplant in Autism and Autism Spectrum Disorder, sponsored by ProgenaBiome. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by ProgenaBiome · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in adult subjects with ASD for treatment of social deficits and language delays.

Read the detailed description

This is an open-label clinical trial to evaluate the benefits of familial fecal microbiota transplant following a 6-week treatment with Vancomycin in adult subjects with ASD for treatment of social deficits and language delays. Participants are given FMT by colonoscopy

02

Conditions studied

  • Autism
  • Autism Spectrum Disorder

Keywords

  • microbiome
  • dysbiosis
  • FMT
  • fecal transpant
  • fecal microbiota transplant
03

In context

Autistic Disorder

1,030 studies on the registry are indexed under Autistic Disorder; 266 are open to participants now.

This study's planned enrollment of 10 is below the median of 49 across 811 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

ProgenaBiome is the lead sponsor of 47 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject at least six years of age.
  2. Subject has confirmed diagnosis of ASD based on the .
  3. Subject with ASD whose parents/caregiver/guardian/LAR can complete process.
  4. A reliable parent or caregiver who can report the side effects and communicate effectively with the research team.
  5. Comorbid gastrointestinal symptoms
  6. Stable medications during the two months prior to enrollment.
  7. Currently receiving interventions in the community or school for ASD.
  8. If female and of , must be willing to utilize at least one highly effective method of for the duration of the study. This includes oral birth control pills, contraceptive implants, and intra-uterine devices. Diaphragms and condoms are not considered highly effective. Subjects not of will be exempt (e.g., , surgically sterilized)
  9. If male, and partner is of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes oral birth control pills, contraceptive implants, and intra-uterine devices Diaphragms and condoms are not considered highly effective. Subjects not of reproductive potential will be exempt (surgically sterilized)

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or intend to become pregnant during the study period.
  2. Subjects whose caregivers are unable/unwilling to cooperate with the protocol requirements.
  3. Subject will be excluded who are suffering with Rett syndrome and Childhood Disintegrative Disorder.
  4. Other serious co-morbid medical disorders affecting brain function and behavior, including uncontrolled seizures.
  5. Subjects unable to refrain from taking non-study antibiotics for the period of the study.
  6. Subjects diagnosed with cancer, except small localized basal cell carcinoma.
  7. Subjects known to abuse alcohol or drugs.
  8. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled for these procedures.
  9. Infection with .
  10. Infection with or C.
  11. Allergy to benzodiazepine.
  12. Inability to stop loperamide, diphenoxylatye/atropine, or cholestyramine before the study
  13. Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no dose increase planned for the duration of the study
  14. Known positive stool cultures for enteropathogens including, but not limited to Shigella, Salmonella, and Campylobacter within 30 days before enrollment. (These infection agents should be treated in advance of participation in this FMT study because they affect the good flora).
  15. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment. (Same as above).
  16. Planned travel outside United States during study period.
  17. to vancomycin
  18. Renal insufficiency
  19. Colitis
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Autism Subjects

    These subjects will be administered fecal microbiota transplant by colonoscopy

    Biological: Fecal Microbiota Transplant

Interventions

06

What researchers measure

Primary outcomes

  1. ATEC

    Number of participants with changes in the Autism Treatment Evaluation Checklist scores

    Time frame: 52 Weeks

  2. QoLA

    Number of participants with changes in Quality of Life Autism scores

    Time frame: 52 Weeks

  3. CARS-2

    Number of participants with changes in Childhood Autism Rating Scale 2 scores

    Time frame: 52 Weeks

  4. SRS-2

    Number of patients with changes in SRS-2 scores

    Time frame: 52 weeks

  5. Behavioral changes

    Changes in reported incidence of disturbances in non-core aspects of behavior or function

    Time frame: 52 weeks

  6. GSRS

    Number of patients with reported changes in GSRS measure of GI disturbances

    Time frame: 52 weeks

  7. abbrvCDAI

    Number of patients with changes in abbrevCDAI scores

    Time frame: 52 weeks

  8. HSPP

    Number of subjects with changes in quality of life metric HSPP

    Time frame: 52 weeks

Secondary outcomes

  1. Shannon Diversity Index

    Changes in Shannon Diversity index compared between pre and post FMT scores

    Time frame: 52 Weeks

  2. Microbiome changes

    Number of subjects with changes to microbiome relative abundance and composition

    Time frame: 52 weeks

Other outcomes

  1. Adverse Events

    Number of participants with grade III or higher adverse events

    Time frame: 52 Weeks

  2. Serious Adverse Events

    Number of participants with serous adverse events

    Time frame: 52 Weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — HIPAA

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Jul 2027, 2 months later.

Of 19 phase 1 interventional studies under Autistic Disorder, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Nov 16, 2020
StartEst.
May 2027
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04630847
Lead sponsor
ProgenaBiome
Collaborators
Ventura Clinical Trials, Microbiome Research Foundation
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
May 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Sabine Hazan, MD
Contact
drhazan@progenabiome.com
18053390549
Jordan Daniels, MS
Contact
jordan@progenabiome.com
18053390549
Sabine Hazan, MD
study director · ProgenaBiome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fecal microbiota

Start the discussion